Adjuvant bisphosphonates: A new standard of care?

Current Opinion in Oncology

Volumn 24, Issue 6, 2012, Pages 635-642

  Gnant, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

adjuvant therapy; anticancer; bisphosphonate; breast cancer

Indexed keywords

ANASTROZOLE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; GOSERELIN; IBANDRONIC ACID; LETROZOLE; PLACEBO; TAMOXIFEN; ZOLEDRONIC ACID;

ADJUVANT THERAPY; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; DIARRHEA; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG EFFICACY; FEMALE; FOLLOW UP; HAZARD RATIO; HEALTH CARE QUALITY; HUMAN; HYPERTRANSAMINASEMIA; HYPOCALCEMIA; OVERALL SURVIVAL; OVULATION INHIBITION; PANCREATITIS; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVIEW; RISK FACTOR; RISK REDUCTION; STATISTICAL SIGNIFICANCE; THROMBOSIS;

ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; FEMALE; HUMANS; MENOPAUSE; STANDARD OF CARE;

EID: 84868206373     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32835771aa     Document Type: Review

References (34)

1. Cardoso F, Costa A, Norton L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012; 21:242-247.
2. Gralow JR, Biermann JS, Farooki A, et al. NCCN Task Force Report: bone health in cancer care. J Natl Compr Canc Netw 2009; 7 (Suppl. 3):S1-S32; quiz S33-S35.
3. Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011; 29:1221-1227.
4. Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract 2010; 16:1016-1019.
5. Hadji P, Aapro MS, Body JJ, et al. Management of aromatase inhibitorassociated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 2011; 22:2546-2555.
6. Rizzoli R, Body JJ, De Censi A, et al. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Osteoporos Int 2012 [Epub ahead of print].
7. Green JR, Guenther A. The backbone of progress-preclinical studies and innovations with zoledronic acid. Crit Rev Oncol Hematol 2011; 77 (Suppl. 1):S3-S12.
8. Winter MC, Holen I, Coleman RE. Exploring the antitumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008; 34: 453-475.
9. Goel S, Sharma R, Hamilton A, et al. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev 2009; (4):CD004562.
10. Chlebowski RT. Bone health in women with early-stage breast cancer. Clin Breast Cancer 2005; 5 (2 Suppl.):S35-S40.
11. Rugo HS. Strategies for the prevention of treatment-related bone loss in women receiving adjuvant hormonal therapy. Clin Breast Cancer 2007; 7 (Suppl. 1):S21-S28.
12. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008; 9:840-849.
13. Mobus V, Diel IJ, Elling D, et al. GAIN study: a phase III trial to compare ETC vs EC-TX and ibandronate vs observation in patients with node-positive primary breast cancer-1st interim efficacy analysis. Presented at 34th Annual San Antonio Breast Cancer Symposium; 6-10 December 2011; San Antonio, TX. Abstract S2-S4.
14. Paterson AHG, Anderson SJ, Lembersky BC, et al. NSABP Protocol B-34: a clinical trial comparing adjuvant clodronate vs placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy-final analysis. Presented at 34th Annual San Antonio Breast Cancer Symposium; 6-10 December 2011; San Antonio, TX. Abstract S2-S3.
15. Southwest Oncology Group. Phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer. Available at http://www.clinicaltrials.gov/ ct2/show/NCT00127205?term=SWOG+0307&rank=2.
16. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Long-term follow-up in ABCSG-12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine-receptor-positive early breast cancer. Presented at 34th Annual San Antonio Breast Cancer Symposium; 6-10 December 2011; San Antonio, TX. Abstract S1-S2.
17. Gnant M, Mlineritsch B, Stoeger H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011; 12:631-641.
18. Coleman RE, Marshall H, Cameron D, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011; 365:1396-1405.
19. de Boer RH, Bundred N, Eidtmann H, et al. Long-term survival outcomes among postmenopausal women with hormone receptor-positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5-year follow-up of ZO-FAST [oral]. Presented at 34th Annual San Antonio Breast Cancer Symposium; 6-10 December 2011; San Antonio, TX. Abstract S1-S3.
20. Coleman RE, de Boer R, Eidtmann H, et al. Influence of delayed zoledronic acid initiation on disease-free survival in postmenopausal women with endocrine receptor-positive early breast cancer receiving adjuvant letrozole: exploratory analyses from the ZO-FAST trial [poster]. Presented at 34th Annual San Antonio Breast Cancer Symposium; 6-10 December 2011; San Antonio, TX. Poster P2-17-01.
21. Pfeiler G, Konigsberg R, Fesl C, et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol 2011; 29:2653-2659.
22. Perrone F, Gallo C, Lastoria S, et al. Bone effects of adjuvant tamoxifen (T), letrozole (L), or L plus zoledronic acid in early breast cancer (EBC): the phase III HOBOE study. J Clin Oncol 2011; 29 (15 Suppl.):Abstract 517.
23. Pfeiler G, Konigsberg R, Fesl C, et al. Impact of body mass index (BMI) on the efficacy of zoledronic acid in premenopausal patients with hormone receptor positive breast cancer: an analysis of the ABCSG-12 trial [poster]. Presented at American Society of Clinical Oncology Annual Meeting; 1-5 June 2012; Chicago, IL. Abstract 514.
24. Brufsky AM, Harker WG, Beck JT, et al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 2012; 118:1192-1201.
25. Llombart A, Frassoldati A, Paija O, et al. Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer 2012; 12:40-48.
26. Marshall H, Gregory W, Bell R, et al. Adjuvant therapy with zoledronic acid (AZURE-BIG 01/04): the influence of menopausal status and age on treatment effects [oral]. Presented at American Society of Clinical Oncology Annual Meeting; 1-5 June 2012: Chicago, IL. Abstract 502.
27. Valachis A, Nearchou A, Polyzos NP, et al. Adjuvant therapy with zoledronic acid in primary breast cancer: a systematic review and meta-analysis [poster]. Eur J Cancer 2011; 47 (Suppl. 1):S377; Abstract 5157.
28. Yan T, Yin W, Zhou Q, et al. The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials. Eur J Cancer 2012; 48:187-195.
29. Gregory W, Marshall H, Bell R, et al. Adjuvant zoledronic acid (ZOL) in postmenopausal women with breast cancer and those rendered postmenopausal: results of a meta-analysis [poster]. Presented at 48th Annual Meeting of the American Society of Clinical Oncology; 1-5 June 2012; Chicago, IL. Abstract 513.
30. Rossi E, Morabito A, Di Rella F, et al. Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol 2009; 27:3192-3197.
31. Neville-Webbe HL, Coleman RE, Holen I. Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction. Br J Cancer 2010; 102:1010-1017.
32. Shiozawa Y, Havens AM, Pienta KJ, et al. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 2008; 22:941-950.
33. Aft R, Naughton M, Trinkaus K, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010; 11:421-428.
34. Solomayer EF, Gebauer G, Hirnle P, et al. Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients. Ann Oncol 2012; 23:2271-2277.